BELIeVE with BLE
We have release to discuss a case study from a customer. Early in 2023, an issue arose around Bluetooth LE. Specifically, there was a question of the bandwidth available to cell phones. Reports had been received of differing behaviours with different handsets. We set out to investigate.
What we found surprised us. We were able to reproduce lower bandwidth results from the field on our test equipment, without having to buy a lot of handsets for testing. Armed with this knowledge, future testing can be automated.
Getting to this stage took some effort customising the BLE library. We had to figure out how to control the bandwidth settings, and expose methods to our runtime.
Read more here!
From Concept to Clinical-Ready Technology
Bermondsey Electronics was responsible for bringing up the operating system and developing the core application running on the device. This included designing a system architecture capable of supporting both current commercial needs and future regulatory pathways.
A key focus was ensuring the device could evolve into a fully regulated medical product without incurring unnecessary cost or delay. To achieve this, Bermondsey implemented the following:
- Separation of user interface and safety-critical functionality
- Isolation of timing- and safety-critical code into a compact, analysable codebase
- Built-in traceability to support future medical device approval
This approach enables Photon Therapeutics to scale efficiently, keeping compliance pathways open whilst ensuring cost control is maintained during earlier stages of market entry.
Engineering for Safety, Reliability and Speed
Given the nature of UVC-based solutions to treat infections, safety and reliability were paramount.
Bermondsey Electronics developed timing-critical control systems with integrated checks and balances, alongside multiple watchdog mechanisms to ensure that any system fault results in a safe and observable outcome. The team also contributed to Failure Modes and Effects Analysis (FMEA), ensuring that all potential risks were identified and mitigated beforehand.
In parallel, the user interface was developed in Qt5, a strategic choice that avoided ongoing licensing costs whilst delivering a responsive and adaptable UX aligned with client requirements.
Agile Development in a Fast-Moving Environment
As Photon Therapeutics navigated the challenges of a growing business, including shifting regulatory strategy and budget constraints, Bermondsey provided flexible, responsive support.
This included:
- Adapting development to align with a move toward the veterinary (unregulated) market
- Delivering rapid fixes and updates based on end-user feedback
- Supporting continued product shipment through fast turnaround solutions to hardware and battery issues
- Providing test reports and validation aligned with available budgets
Crucially, throughout the development process, Bermondsey Electronics maintained production code while preserving the ability to reintroduce deferred features as the product evolves.
Enabling a New Standard in Infection Treatment
Photon Therapeutics’ award-winning UVC Vet treatment device represents a significant step forward in infection treatment. By utilising UVC light, it offers a number of benefits which include:
- Rapid, single-course treatment
- Consistent elimination of infections
- Reduced reliance on pharmaceuticals
- Lower risk of antimicrobial resistance
The impact of this innovative technology was recognised at the 2026 Animal Health & Nutrition Technology Innovation European Summit, where Photon Therapeutics received the Technology Award.
Don’t just take our word for it.
Hear from our customers.
Contact Us
If you have questions about how we can help your business please complete the form below and we will be in touch shortly.
Alternatively, please call us on +44 (0)208 0650 162
Email : [email protected]